<DOC>
	<DOCNO>NCT02829840</DOCNO>
	<brief_summary>The goal Part 1 clinical research study learn ponatinib alone help control FLT3-mutated AML FLT3-mutated high-risk MDS . The safety drug also study . The goal Part 2 clinical research study find high tolerable dose ponatinib combination 5-azacytidine learn high dose level find help control FLT3-mutated AML FLT3-mutated high-risk MDS . The safety combination also study .</brief_summary>
	<brief_title>Dose-Escalation Study Ponatinib , FLT3 Inhibitor , With Without Combination 5-Azacytidine , Patients With FLT3-Mutated Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , assign either Part 1 Part 2 base join study . If participant enrol Part 1 , receive ponatinib alone first cycle . If doctor think need , dose level may increase . If disease respond ponatinib alone , participant continue Part 2 study . Part 2 clinical research study 2 phase : Phase 1 ( dose escalation ) Phase 2 ( dose expansion ) . In Part 2 , participant assign study group base join study . Up 3 group 30 participant enrol Phase 1 Part 2 , 60 participant enrol Phase 2 . If participant enrol Phase 1 , dose ponatinib receive depend join study . The first group participant receive low dose level ponatinib . Each new group receive high dose ponatinib group , intolerable side effect see . This continue high tolerable dose ponatinib find . If participant enrol Phase 2 , receive ponatinib high dose tolerate Phase 1 . All participant Part 2 receive dose level 5-azacytidine . Study Drug Administration : Each study cycle 28 day . Participant take ponatinib tablet mouth 1 time every day study . Participant swallow tablet whole . Participant crush . If participant enrol Part 2 , receive 5-azacytidine either vein 1 hour injection skin Days 1-7 study cycle Days 1-5 , 8 , 9 study cycle ( clinic close weekend ) . If doctor think need , dose level , dose schedule , study cycle may change and/or delay . The study doctor discus change participant . Study Visits : On Day 1 cycle ( +/- 4 day ) , participant physical exam . On Day 1 ( +/-1 day ) Cycles 1-3 every 3 cycle ( Cycles 6 , 9 , 12 , ) , participant EKG . On Day 1 Cycle 2 every 3 cycle , participant ECHO MUGA perform . One ( 1 ) time week Cycles 1-3 1 time every 2-4 week , blood ( 1 tablespoon ) drawn routine test . Participant may able blood draw perform local lab clinic closer home . The result test send MD Anderson review . On Day 28 ( +/- 7 day ) Cycles 1 , 3 , every 1-3 cycle , participant bone marrow aspiration/biopsy check status disease . One ( 1 ) time every 3 cycle , participant become pregnant , blood ( 1-2 tablespoon ) draw pregnancy test . At time participant study , doctor think need : - Blood ( 1-2 tablespoon ) draw routine test . - Participant may bone marrow aspiration/biopsy check status disease . Length Study : Participant receive ponatinib alone ponatinib 5-azacytidine long doctor think best interest . Participant longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Patient 's participation study follow-up visit . End-of-Study Visit : Within 14 day participant 's last dose study drug ( ) : - Participant physical exam . - Blood ( 2-3 tablespoon ) draw routine test . - If doctor think need , participant bone marrow aspirate/biopsy check status disease . Follow-Up : About 30 day end-of-study visit , member study staff call participant ask side effect and/or start new treatment ( ) . This call last 5 minute . If study staff think need , participant may also ask come clinic physical exam . Long-Term Follow-Up : If disease appear respond study drug , member study staff call participant every 3-6 month 5 year ask side effect may . Each call last 5 minute . Participant may also ask come clinic physical exam , study staff think need . This investigational study . 5-azacytidine FDA approve commercially available treatment myelodysplastic syndrome ( MDS ) . Ponatinib commercially available FDA approve treatment specific group chronic myeloid leukemia ( CML ) participant . Their use study consider investigational . The study doctor explain study drug design work . Up 132 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>1 . Patients diagnosis AML ( de novo transform hematologic malignancy ) , MDS chronic myelomonocytic leukemia ( CMML ) one follow feature : ( A ) Patients MDS CMML fail prior therapy hypomethylating agent and/or lenalidomide ( Cohorts 2 3 ) . ( B ) Patients AML fail prior therapy relapse prior therapy ( Cohorts 2 3 ) . For patient Cohort 3 prior therapy include FLT3 inhibitor . ( C ) Patients MDS CMML receive therapy hypomethylating agent progress AML eligible time diagnosis AML regardless prior therapy AML . The World Health Organization ( WHO ) classification use AML . These patient assign Cohort 1 . Patients MDS , CMML AML receive prior therapy eligible age 65 great , time enrollment , candidate receive refuse standard therapy ( Cohort 1 ) 2 . Patients FLT3 mutation , either ITD kinase domain mutation activation loop mutation . 3 . Age &gt; /= 18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 2 5 . Adequate hepatic ( serum total bilirubin &lt; 2.0 x upper limit normal ( ULN ) ( &lt; 3.0 x ULN deem elevated due leukemia Gilbert 's syndrome ) , alanine aminotransferase and/or aspartate transaminase &lt; 3.0 x ULN ( &lt; 5.0 x ULN deem elevated due leukemia ) , renal function ( creatinine 2x ULN glomerular filtration rate ( GFR ) &gt; 50 ) function . 6 . Left ventricular ejection fraction ( LVEF ) least 40 % multiple gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) 7 . Patients must provide write informed consent . 8 . In absence rapidly progress disease , interval prior treatment time initiation ponatinib administration least 2 week cytotoxic agent OR least 5 halflives cytotoxic/noncytotoxic agent . Use one dose cytarabine ( 2 g/m2 ) hydroxyurea patient rapidly proliferative disease allow start study therapy first eight week study therapy day enrollment , either prior concomitantly ponatinib administration initially control peripheral blast count . Concurrent therapy central nervous system ( CNS ) prophylaxis continuation therapy control CNS disease permit . Controlled CNS leukemia define absence active clinical sign CNS disease evidence CNS leukemia recent 2 simultaneous cerebrospinal fluid ( CSF ) evaluation . 9 . Women childbearing potential must practice contraception . Females childbearing potential : Recommendation 2 effective contraceptive method study . Adequate form contraception double barrier method ( condom spermicidal jelly foam diaphragm spermicidal jelly foam ) , oral , depo provera , injectable contraceptive , intrauterine device , tubal ligation . Male patient female partner childbearing potential : Recommendation male partner use least 2 effective contraceptive method , describe , study . 10 . Females must surgically biologically sterile postmenopausal ( amenorrheic least 12 month ) childbearing potential , must negative urine pregnancy test within 72 hour serum pregnancy test within 2 week sign Informed Consent document . 11 . Women childbearing potential must agree use adequate method contraception study 3 month last treatment . Males must surgically biologically sterile agree use adequate method contraception study 3 month last treatment . Adequate method contraception include : ( A ) Total abstinence line prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . ( B ) Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment 12 . 11 ( Cont 'd ) : ( C ) Male sterilization ( least 6 month prior screen ) . For female patient study , vasectomize male partner sole partner patient ( D ) Combination two follow ( a+b a+c b+c ) : ( 1 ) Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception ( B ) Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . ( C ) Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/ vaginal suppository In case use oral contraception , woman stable pill take study treatment . Note : Oral contraceptive allow used conjunction barrier method contraception due unknown effect drugdrug interaction . 13 . 11 ( Cont 'd ) Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 14 . 1 ( Cont 'd ) consider candidate intensive remission induction chemotherapy time enrollment base EITHER : 1 . &gt; /= 75 year age OR 2 . &lt; 75 year age least 1 following : A . Poor performance status ( ECOG ) score 23 B. Clinically significant heart lung comorbidities , reflect least 1 : ( ) Left ventricular ejection fraction &lt; /= 50 % , ( ii ) Lung diffuse capacity carbon monoxide ( DLCO ) &lt; /= 65 % expect , ( iii ) force expiratory volume 1 second ( FEV1 ) &lt; /= 65 % expect , ( iv ) congestive heart failure ( CHF ) C. Serum creatinine &gt; 2 mg/dL , dialysis history renal transplant . D. Other contraindication ( ) anthracycline therapy ( must document ) . E. Other comorbidity investigator judge incompatible intensive remission induction chemotherapy , must document approve PI randomization . 1 . Patients know allergy hypersensitivity ponatinib , 5azacytidine , component . 2 . Patients receive treatment ponatinib prior study entry . 3 . History acute pancreatitis within 1 year study history chronic pancreatitis . 4 . History alcohol abuse . 5 . Uncontrolled infection time enrollment . Infections control concurrent antimicrobial agent acceptable , antimicrobial prophylaxis per institutional guideline acceptable . 6 . Active secondary malignancy skin cancer ( e.g. , basal cell carcinoma squamous cell carcinoma ) investigator 's opinion shorten survival less 1 year . 7 . Cardiac Symptoms : Patients meet follow criterion eligible : History unstable angina , myocardial infarction , transient ischemic attack ( TIA ) , stroke , peripheral arterial occlusive disease , venous thromboembolism pulmonary embolism . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) . Prolonged correct QT interval ( QTc ) interval preentry electrocardiogram ( &gt; 470 msec ) Fridericia Bazett 's correction . Symptomatic congestive heart failure within 3 month prior first dose ponatinib ( NYHA class III IV ) . 8 . Patients uncontrolled hypertension ( define sustain stage 2 hypertension , i.e. , systolic BP &gt; /=160 mmHg diastolic BP &gt; /=100 mmHg ) without medical therapy . 9 . Patients currently take drug generally accept risk cause Torsades de Pointes ( unless change acceptable alternative ) . 10 . Taking medication herbal supplement know strong inhibitor CYP3A4 within least 14 day first dose ponatinib . 11 . Patients major surgical procedure within 14 day Day 1 . 12 . Patients unwilling unable comply protocol . 13 . History significant bleeding disorder unrelated cancer , include : • Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) • Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) 14 . Patients inflammatory chronic functional bowel disorder , Crohn disease , inflammatory bowel disease , gastrointestinal graft versus host disease opinion investigator may interfere absorption ponatinib increase risk serious complication . 15 . Any medical , psychological , social condition may interfere study participation compliance , compromise patient safety opinion investigator . 16 . Known active hepatitis B virus ( HBV ) C virus ( HCV ) infection ; know positive HCV ribonucleic acid ( RNA ) HBsAg ( HBV surface antigen ) . 17 . Known human immunodeficiency virus ( HIV ) infection . 18 . Patients time enrollment , willing eligible receive stem cell transplant eligible participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>FLT3-Mutated Acute Myeloid Leukemia</keyword>
	<keyword>FLT3-Mutated High-Risk Myelodysplastic Syndrome</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Ponatinib</keyword>
	<keyword>Iclusig</keyword>
	<keyword>AP24534</keyword>
	<keyword>5-azacytidine</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>Azacytidine</keyword>
</DOC>